Inventor profile of:

Matthew During

City:

Weston, Connecticut

Country:

United States

Published Applications:

95

Last publication date:

2023-05-18

Top Assignees for applications by Matthew During

The entities that hold a legal rights for patent applications filed by inventor During Matthew:

Recent patent applications by During Matthew

Matthew During from Weston, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2023-05-18
US20230149332A1
Human necessities

Methods of treating seizure disorders and Prader-Willi syndrome

#2 | 2022-08-04
US20220241253A1
Human necessities

USE OF GABOXADOL IN THE TREATMENT OF SUBSTANCE USE DISORDERS

#3 | 2022-01-20
US20220016091A1
Human necessities

METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA

#4 | 2021-12-09
US20210379028A1
Human necessities

TREATMENT OF DEPRESSIVE DISORDERS

#5 | 2021-12-02
US20210371880A1
Chemistry; metallurgy

RECOMBINANT ADENO-ASSOCIATED VECTORS

#6 | 2021-09-16
US20210283075A1
Human necessities

METHODS OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER

#7 | 2021-07-15
US20210213000A1
Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#8 | 2021-06-24
US20210186938A1
Human necessities

Gaboxadol for therapeutic treatment of 1p36 deletion syndrome

#9 | 2021-06-17
US20210177805A1
Human necessities

USE OF GABOXADOL IN THE TREATMENT OF GASTROINTESTINAL TRACT DISORDERS AND ASTHMA

#10 | 2021-04-08
US20210100763A1
Human necessities

Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

#11 | 2021-04-01
US20210095292A1
Chemistry; metallurgy

Use of MIR101 or MIR128 in the treatment of seizure disorders

#12 | 2021-02-04
US20210030728A1
Human necessities

Use of gaboxadol in the treatment of diabetes and related conditions

#13 | 2021-02-04
US20210030727A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL

#14 | 2021-01-21
US20210015760A1
Human necessities

PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENT

#15 | 2021-01-07
US20210000805A1
Human necessities

Methods and compositions for treatment of epileptic disorders

#16 | 2020-12-03
US20200375960A1
Human necessities

Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering

#17 | 2020-10-22
US20200332294A1
Chemistry; metallurgy

Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome

#18 | 2020-08-06
US20200246293A1
Human necessities

Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction

#19 | 2020-07-16
US20200222372A1
Human necessities

USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSY

#20 | 2020-06-18
US20200188365A1
Human necessities

Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder

#21 | 2020-06-11
US20200179351A1
Human necessities

TREATMENT OF DEPRESSIVE DISORDERS

#22 | 2020-06-11
US20200179350A1
Human necessities

Methods and compositions for treatment of epileptic disorders

#23 | 2020-05-07
US20200138785A1
Human necessities

USE OF GABOXADOL, GANAXOLONE AND ALLOPREGNANOLONE TO TREAT MOVEMENT DISORDERS

#24 | 2020-03-26
US20200093806A1
Human necessities

Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering

#25 | 2020-01-02
US20200000813A1
Human necessities

Methods of treating developmental disorders and/or seizure disorders with etifoxine

#26 | 2020-01-02
US20200000757A1
Human necessities

METHODS OF TREATING SEIZURE DISORDERS AND PRADER-WILLI SYNDROME

#27 | 2019-12-19
US20190382761A1
Chemistry; metallurgy

Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome

#28 | 2019-12-12
US20190374492A1
Human necessities

Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

#29 | 2019-11-21
US20190350882A1
Human necessities

METHODS OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER

#30 | 2019-10-31
US20190328719A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE

#31 | 2019-10-24
US20190321342A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL

#32 | 2019-10-24
US20190321341A1
Human necessities

USE OF GABOXADOL IN THE TREATMENT OF SUBSTANCE USE DISORDERS

#33 | 2019-10-10
US20190307733A1
Human necessities

Methods and compositions for treatment of epileptic disorders

#34 | 2019-10-03
US20190298674A1
Human necessities

USE OF (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF EYE DISORDERS

#35 | 2019-08-22
US20190255027A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL

#36 | 2019-08-15
US20190247394A1
Human necessities

Methods of treating developmental syndromes with PDE10A inhibitors

#37 | 2019-08-08
US20190240174A1
Human necessities

Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction

#38 | 2019-07-18
US20190216785A1
Human necessities

Methods and compositions for treatment of epileptic disorders

#39 | 2019-06-20
US20190184034A1
Human necessities

USE OF hM4Di IN THE TREATMENT OF SEIZURE DISORDERS

#40 | 2019-06-06
US20190169619A1
Chemistry; metallurgy

Use of MIR101 or MIR128 in the treatment of seizure disorders

#41 | 2019-04-25
US20190117633A1
Human necessities

TREATMENT OF DEPRESSIVE DISORDERS

#42 | 2019-04-25
US20190117632A1
Human necessities

Methods of treating developmental disorders with gaboxadol

#43 | 2019-04-18
US20190111033A1
Human necessities

USE OF GABOXADOL IN THE TREATMENT OF TINNITUS

#44 | 2019-04-11
US20190105308A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE

#45 | 2019-03-28
US20190091231A1
Human necessities

Methods of treating developmental disorders and/or seizure disorders with etifoxine

#46 | 2019-03-28
US20190091209A1
Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#47 | 2019-03-21
US20190085358A1
Chemistry; metallurgy

RECOMBINANT ADENO-ASSOCIATED VECTORS

#48 | 2019-03-14
US20190076415A1
Human necessities

Methods of treating behavioral syndromes using pipradrol

#49 | 2019-03-14
US20190076409A1
Human necessities

USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSY

#50 | 2019-02-28
US20190060400A1
Human necessities

USE OF DESIGNER RECEPTORS EXCLUSIVELY ACTIVATED BY DESIGNER DRUGS AND ULTRASOUND IN THE TREATMENT OF SEIZURE DISORDERS

#51 | 2019-02-14
US20190046480A1
Human necessities

Methods of treating developmental disorders with biguanides

#52 | 2019-02-07
US20190038606A1
Human necessities

Use of Gaboxadol in the treatment of diabetes and related conditions

#53 | 2019-01-03
US20190000993A1
Human necessities

TREATMENT OF DEVELOPMENTAL SYNDROMES

#54 | 2018-12-06
US20180344745A1
Human necessities

TREATMENT OF DEVELOPMENTAL DISORDERS WITH IMIDAZOLONE DERIVATIVES

#55 | 2018-12-06
US20180344709A1
Human necessities

Use of gaboxadol in the treatment of tinnitus

#56 | 2018-12-06
US20180344708A1
Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#57 | 2018-11-29
US20180338960A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL

#58 | 2018-11-29
US20180338959A1
Human necessities

TREATMENT OF DEPRESSIVE DISORDERS

#59 | 2018-10-25
US20180303805A1
Human necessities

Methods for treating aggression associated with Alzheimer's disease

#60 | 2018-10-18
US20180296501A1
Human necessities

Methods of treating developmental encephalopathies

#61 | 2018-08-30
US20180243266A1
Human necessities

Methods of treating seizure disorders

#62 | 2018-08-23
US20180235942A1
Human necessities

METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING CRITICAL CARE TREATMENT

#63 | 2018-08-09
US20180221355A1
Human necessities

Use of gaboxadol in the treatment of tinnitus

#64 | 2018-08-09
US20180221319A1
Human necessities

METHODS OF TREATING SEIZURE DISORDERS AND PRADER-WILLI SYNDROME

#65 | 2018-05-31
US20180147195A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS USING PIPRADROL

#66 | 2018-05-24
US20180140586A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS AND/OR SEIZURE DISORDERS WITH FLUPIRTINE

#67 | 2018-04-12
US20180098974A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL

#68 | 2018-02-22
US20180050001A1
Human necessities

Methods of treating developmental disorders with biguanides

#69 | 2018-02-15
US20180042903A1
Human necessities

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

#70 | 2018-02-08
US20180036298A1
Human necessities

METHODS OF TREATING BEHAVIORAL SYNDROMES USING PIPRADROL

#71 | 2018-01-18
US20180015076A1
Human necessities

METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA

#72 | 2017-12-07
US20170348255A1
Human necessities

Methods of treating Prader-Willi syndrome

#73 | 2017-12-07
US20170348232A1
Human necessities

FORMULATIONS OF GABOXADOL FOR TREATMENT OF ANGELMAN SYNDROME, FRAGILE X SYNDROME AND FRAGILE X-ASSOCIATED TREMOR/ATAXIA SYNDROME

#74 | 2017-11-30
US20170340619A1
Human necessities

Methods of treating behavioral syndromes using pipradrol

#75 | 2017-11-09
US20170319556A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS USING GABOXADOL

#76 | 2017-10-19
US20170296519A1
Human necessities

Methods of sedation during critical care treatment

#77 | 2017-09-28
US20170273956A1
Human necessities

METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA

#78 | 2017-08-31
US20170246152A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS USING GABOXADOL

#79 | 2017-08-03
US20170216269A1
Human necessities

Methods of treating developmental disorders using pipradrol

#80 | 2017-05-04
US20170119704A1
Human necessities

TREATMENT OF COGNITIVE IMPAIRMENT

#81 | 2017-03-30
US20170087133A1
Human necessities

Methods of increasing tonic inhibition and treating secondary insomnia

#82 | 2017-03-16
US20170071917A1
Human necessities

Methods of treatment Rett syndrome

#83 | 2017-03-09
US20170065572A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS USING PIPRADROL

#84 | 2017-02-16
US20170042863A1
Human necessities

Methods of sedation during critical care treatment

#85 | 2017-01-19
US20170014393A1
Human necessities

METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH GABOXADOL

#86 | 2017-01-19
US20170014392A1
Human necessities

Methods of treating Dravet syndrome

#87 | 2016-12-01
US20160346232A1
Human necessities

Methods of treating Prader-Willi Syndrome

#88 | 2016-11-03
US20160317477A1
Human necessities

METHODS OF TREATING PRADER-WILLI SYNDROME

#89 | 2016-08-11
US20160228418A1
Human necessities

Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome

#90 | 2016-08-04
US20160220479A1
Human necessities

TOPICAL COMPOUNDS CONTAINING ADIPOSE-DERIVED HORMONES FOR THE REJUVENATION OF SKIN

#91 | 2016-07-26
US14834027
Human necessities

Methods of sedation during critical care treatment

#92 | 2016-05-31
US14876110
Human necessities

Methods of treating developmental disorders using pipradrol

#93 | 2016-02-11
US20160038469A1
Human necessities

Methods of increasing tonic inhibition and treating secondary insomnia

#94 | 2015-12-10
US20150352085A1
Human necessities

METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA

#95 | 2015-11-05
US20150313903A1
Human necessities

METHODS OF TREATING COGNITIVE IMPAIRMENT ASSOCIATED WITH NEURODEGENERATIVE DISORDERS

InventorID:

1344331 ⎘